2016 Fiscal Year Final Research Report
Development of measles virus vector-based vaccine against highly pathogenic avian influenza virus
| Project/Area Number |
26870147
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Veterinary medical science
Virology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
KAI Chieko 東京大学, 医科学研究所, 教授 (10167330)
YONEDA Misako 東京大学, 医科学研究所, 准教授 (40361620)
KOHARA Michinori 東京都医学総合研究所, ゲノム医科学研究分野, シニア研究員 (10250218)
KIDA Hiroshi 北海道大学, 人獣共通感染症リサーチセンター, 特任教授 (10109506)
HATTORI Shosaku 東京大学, 医科学研究所, 特任研究員 (00164864)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 高病原性鳥インフルエンザウイルス / 麻疹ウイルス / カニクイザル / 感染モデル / 発症防御 / ワクチン / ベクター |
|---|
| Outline of Final Research Achievements |
We generated recombinant measles virus (rMV) expressing the hemagglutinin (HA) protein of HPAIV (H5), and examined protective efficacy of the candidate vaccine in the monkey infection model by the challenge with a HPAIV (H5N1). Cynomolgus monkeys inoculated with the candidate vaccine produced anti-H5 HA antibodies and recovered earlier from influenza symptoms than unvaccinated monkeys after the challenge with the HPAIV strain. In addition, vaccination tended to suppress viral shedding. Moreover, even in monkeys possessing pre-existing anti-MV antibodies, the vaccination with the candidate induced the production of antibodies against H5 HA. These results suggest that the rMV expressing H5 HA is a good candidate vaccine against HPAIV infection to reduce disease severity.
|
| Free Research Field |
ウイルス学
|
